drugset
drugset / Trial / NCT03207399

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

NCT03207399 ↗

Phase 4 Terminated 1 enrolled Duke University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether treatment with Epclusa (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C infection is feasible, safe and effective at curing HCV.

Timeline

Start
2017-09-15
Primary completion
2019-03-25
Completion
2019-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject glecaprevir Other / unclassified 100 mg Oral
Subject glecaprevir Other / unclassified 400 mg Oral

Indications

chronic hepatitis C virus infection